These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30047603)

  • 1. Synthesis and Biological Evaluation of Tripartin, a Putative KDM4 Natural Product Inhibitor, and 1-Dichloromethylinden-1-ol Analogues.
    Guillade L; Sarno F; Tarhonskaya H; Nebbioso A; Alvarez S; Kawamura A; Schofield CJ; Altucci L; de Lera ÁR
    ChemMedChem; 2018 Sep; 13(18):1949-1956. PubMed ID: 30047603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tripartin, a histone demethylase inhibitor from a bacterium associated with a dung beetle larva.
    Kim SH; Kwon SH; Park SH; Lee JK; Bang HS; Nam SJ; Kwon HC; Shin J; Oh DC
    Org Lett; 2013 Apr; 15(8):1834-7. PubMed ID: 23550720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Studies toward the Natural Product Tripartin, the First Natural Histone Lysine Demethylase Inhibitor.
    Dethe DH; Boda R
    ACS Omega; 2018 Aug; 3(8):9303-9309. PubMed ID: 31459063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
    Le Bihan YV; Lanigan RM; Atrash B; McLaughlin MG; Velupillai S; Malcolm AG; England KS; Ruda GF; Mok NY; Tumber A; Tomlin K; Saville H; Shehu E; McAndrew C; Carmichael L; Bennett JM; Jeganathan F; Eve P; Donovan A; Hayes A; Wood F; Raynaud FI; Fedorov O; Brennan PE; Burke R; van Montfort RLM; Rossanese OW; Blagg J; Bavetsias V
    Eur J Med Chem; 2019 Sep; 177():316-337. PubMed ID: 31158747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
    Leurs U; Clausen RP; Kristensen JL; Lohse B
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzo[
    Kim YJ; Lee DH; Choi YS; Jeong JH; Kwon SH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Novel Benzimidazole Pyrazolone Scaffold That Inhibits KDM4 Lysine Demethylases and Reduces Proliferation of Prostate Cancer Cells.
    Carter DM; Specker E; Przygodda J; Neuenschwander M; von Kries JP; Heinemann U; Nazaré M; Gohlke U
    SLAS Discov; 2017 Aug; 22(7):801-812. PubMed ID: 28346812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
    Chu CH; Wang LY; Hsu KC; Chen CC; Cheng HH; Wang SM; Wu CM; Chen TJ; Li LT; Liu R; Hung CL; Yang JM; Kung HJ; Wang WC
    J Med Chem; 2014 Jul; 57(14):5975-85. PubMed ID: 24971742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors.
    King ON; Li XS; Sakurai M; Kawamura A; Rose NR; Ng SS; Quinn AM; Rai G; Mott BT; Beswick P; Klose RJ; Oppermann U; Jadhav A; Heightman TD; Maloney DJ; Schofield CJ; Simeonov A
    PLoS One; 2010 Nov; 5(11):e15535. PubMed ID: 21124847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
    Rüger N; Roatsch M; Emmrich T; Franz H; Schüle R; Jung M; Link A
    ChemMedChem; 2015 Nov; 10(11):1875-83. PubMed ID: 26337137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity.
    Lee HJ; Kim BK; Yoon KB; Kim YC; Han SY
    Invest New Drugs; 2017 Dec; 35(6):733-741. PubMed ID: 28905188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM4 inhibitor SD49-7 attenuates leukemia stem cell
    Li Y; Wang C; Gao H; Gu J; Zhang Y; Zhang Y; Xie M; Cheng X; Yang M; Zhang W; Li Y; He M; Xu H; Zhang H; Ji Q; Ma T; Ding S; Zhao Y; Gao Y
    Theranostics; 2022; 12(11):4922-4934. PubMed ID: 35836814
    [No Abstract]   [Full Text] [Related]  

  • 13. 4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
    Morera L; Roatsch M; Fürst MC; Hoffmann I; Senger J; Hau M; Franz H; Schüle R; Heinrich MR; Jung M
    ChemMedChem; 2016 Sep; 11(18):2063-83. PubMed ID: 27505861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
    Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
    J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
    Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
    J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.
    Małecki PH; Rüger N; Roatsch M; Krylova O; Link A; Jung M; Heinemann U; Weiss MS
    ChemMedChem; 2019 Nov; 14(21):1828-1839. PubMed ID: 31475772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
    Chin YW; Han SY
    Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Diallo H; Douault C; Drewes G; Eagle R; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Liddle J; Mosley J; Muelbaier M; Randle R; Rioja I; Rueger A; Seal GA; Sheppard RJ; Singh O; Taylor J; Thomas P; Thomson D; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1357-69. PubMed ID: 26771107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-silico guided chemical exploration of KDM4A fragments hits.
    Lombino J; Vallone R; Cimino M; Gulotta MR; De Simone G; Morando MA; Sabbatella R; Di Martino S; Fogazza M; Sarno F; Coronnello C; De Rosa M; Cipollina C; Altucci L; Perricone U; Alfano C
    Clin Epigenetics; 2023 Dec; 15(1):197. PubMed ID: 38129913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.
    Berry WL; Janknecht R
    Cancer Res; 2013 May; 73(10):2936-42. PubMed ID: 23644528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.